From: Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
Female, n (%) | 97 (84.3) |
---|---|
Age, median (IQR) | 50 (44.5–54) |
Medical history, n (%) | |
 Smoking | 23 (20.0) |
 Alcohol abuse | 10 (8.7) |
 Family history of headaches | 78 (67.8) |
 Arterial hypertension | 29 (25.2) |
BMI, median (IQR) | 23 (20–25) |
Headache characteristics, n (%) | |
 Aura | 19 (16.5) |
 Allodynia | 38 (33.0) |
Pain characteristics, n (%) | |
 Unilateral | 48 (41.7) |
 Throbbing | 74 (64.3) |
 Diffuse | 24 (20.9) |
 Frontal | 60 (52.2) |
 Temporal | 59 (51.3) |
 Ocular | 34 (29.6) |
 Occipital | 15 (13.0) |
 Parietal | 15 (13.0) |
 Vertex | 9 (7.8) |
Medication overuse, n (%) | 89 (77.4) |
Preventive treatments in history, n (%) | |
 Antidepressants | 82 (71.3) |
 Anticonvulsants | 69 (60.0) |
 Calcium antagonists | 42 (36.5) |
 Other | 8 (7.0) |
Concurrent oral preventive treatments, n (%) | 61 (53.0) |
Migraine duration (years), median (IQR) | 30 (22–39.5) |
Chronic migraine duration (months), median (IQR) | 62.5 (24–144) |